Current Opinion in Endocrinology, Diabetes and Obesity, published by LIPPINCOTT WILLIAMS & WILKINS, offers a critical analysis of the latest advancements and trends in the fields of endocrinology, diabetes, and obesity. With an ISSN of 1752-296X and an E-ISSN of 1752-2978, this esteemed journal provides an authoritative platform for researchers, clinicians, and healthcare professionals to stay updated on emerging research and clinical practices. Renowned for its impactful contributions, the journal holds notable rankings, including Q2 in Endocrinology and Diabetes & Metabolism, as well as a commendable Q1 in Internal Medicine, reflecting its significance in the academic community. Although currently not an open access publication, articles published from 2007 to 2024 continually enrich the discourse on pressing health issues related to endocrinology and metabolic disorders. By fostering a comprehensive understanding of the complexities within these interconnected fields, it serves as an essential resource for any professional or student engaged in health science research.

Therapeutic Advances in Endocrinology and Metabolism is a premier open-access journal published by SAGE Publications Ltd that has established itself as a leading platform for research in the field of endocrinology, diabetes, and metabolism. With a commitment to disseminating high-quality research, the journal aims to advance our understanding of therapeutic interventions and innovations in the management of endocrine disorders. Since its inception in 2010, it has garnered a strong reputation, attaining a Q1 quartile ranking in 2023 in its category and boasting a respectable Scopus rank of #53 out of 244, positioning it within the 78th percentile. As an open-access journal since 2019, Therapeutic Advances in Endocrinology and Metabolism ensures that valuable research findings are accessible to a global audience, fostering collaboration and knowledge sharing among researchers, clinicians, and students alike. The journal's multifaceted objectives encompass the publication of original research, reviews, and clinical studies that contribute to the evolving dialogue surrounding endocrine health. By delivering timely and robust content, it serves as an indispensable resource for those striving to make significant contributions to this vital area of medical science.

Practical Diabetes is an esteemed journal dedicated to advancing the understanding and management of diabetes and related metabolic disorders. Published by John Wiley & Sons Ltd, this journal serves as a vital resource for healthcare professionals, researchers, and students seeking to explore the latest findings and practical applications in the field of endocrinology. With an ISSN of 2047-2897, it has established itself as a respected outlet for impactful research since its inception in 2011, with a convergence period extending until 2024. Although currently listed in Q4 for Endocrinology, Diabetes, and Metabolism and Q3 for Internal Medicine, the journal is committed to improving its rank and increasing its relevance in a competitive academic landscape. While not an open-access publication, Practical Diabetes provides valuable insights and evidence-based practices that are crucial for improving patient outcomes. Researchers and practitioners alike will find a wealth of knowledge to inform their work and enhance their understanding of diabetes management, making this journal an essential addition to any academic library collection.

JOURNAL OF DIABETES AND ITS COMPLICATIONS is a distinguished peer-reviewed journal published by Elsevier Science Inc, dedicated to advancing the knowledge and management of diabetes and its multifaceted complications. With an ISSN of 1056-8727 and E-ISSN 1873-460X, this journal has established its significance in the fields of Endocrinology, Diabetes and Metabolism, and Internal Medicine, as reflected in its Q2 and Q1 quartile rankings for 2023, and its commendable Scopus rankings. The journal, which has been converging knowledge since 1992 and continues to publish vital research until 2024, serves as a platform for researchers, professionals, and students aiming to delve deeper into the mechanisms, treatment, and implications of diabetes and its related disorders. While access is not open, the journal remains a critical resource for those invested in understanding and combating the challenges posed by diabetes, ultimately contributing to better health outcomes.

ACTA DIABETOLOGICA, published by SPRINGER-VERLAG ITALIA SRL, is a distinguished peer-reviewed journal dedicated to the rapidly evolving fields of endocrinology, diabetes, and metabolism. With an impressive convergence of research from 1991 to 2024, it is recognized for its significant contributions, boasting a Q1 ranking in Internal Medicine and Q2 rankings in Endocrinology categories as of 2023. Its Scopus rankings further highlight its impact, placing it in the 81st percentile in Internal Medicine. The journal serves as a vital platform for professionals and researchers, facilitating the dissemination of innovative findings and fostering a comprehensive understanding of metabolic disorders. Although the journal is not open access, it remains an essential resource, ensuring high visibility and accessibility of critical research to its scholarly audience.

DIABETOLOGIA is a leading journal in the field of endocrinology and diabetes research, published by Springer since its inception in 1965. With an impactful presence in both Internal Medicine and Endocrinology, Diabetes and Metabolism, it is recognized in the Q1 quartile rankings for 2023, underscoring its significance and contribution to these disciplines. The journal holds impressive Scopus rankings, placing it in the top 5% of journals in its categories, making it an essential resource for researchers, healthcare professionals, and students dedicated to advancing knowledge and practices in diabetes care and management. DIABETOLOGIA publishes a range of peer-reviewed articles, original research, and reviews that address the latest scientific developments, clinical practices, and therapeutic innovations, contributing to the global discourse on diabetes and its related health implications. Although it does not offer Open Access options, its rigorous selection process guarantees the quality and relevance of the content, solidifying its position as a reliable reference for contemporary research. For those looking to stay at the forefront of diabetes science, DIABETOLOGIA is a vital communique in the ever-evolving landscape of medical research.

DIABETES OBESITY & METABOLISM, published by Wiley, is a premier international journal dedicated to the fields of endocrinology, diabetes, and metabolic disorders. With an impressive impact factor and its status as a Q1 journal in multiple categories—including Endocrinology and Internal Medicine—this publication is highly regarded in the academic community. Since its inception in 1999, the journal has served as a crucial platform for the dissemination of cutting-edge research, reviews, and clinical studies, driving advancements in understanding and treatment of diabetes and obesity. Researchers and professionals alike benefit from its rigorous peer-review process and extensive reach, as it aims to bridge the gap between laboratory findings and clinical applications. Although not an Open Access journal, articles are accessible through institutional subscriptions, ensuring that vital knowledge reaches those committed to enhancing patient care and expanding the scientific body of work in these pivotal areas.

Metabolic Syndrome and Related Disorders is an esteemed journal published by MARY ANN LIEBERT, INC, focusing on the multifaceted aspects of metabolic syndrome, including its interaction with chronic diseases such as diabetes, cardiovascular conditions, and obesity. Since its inception in 2003, this journal has established itself as a vital resource for researchers, healthcare professionals, and students dedicated to advancing knowledge in the fields of endocrinology, internal medicine, and metabolic disorders. With an impact factor reflective of its academic significance, Metabolic Syndrome and Related Disorders is recognized within the Q2 and Q3 quartiles in its respective categories, solidifying its reputation among scientific and clinical communities. Although it does not currently offer open access options, the journal remains committed to disseminating high-quality research and reviews that foster innovative solutions and improve patient outcomes. The journal's gradual convergence towards 2024 presents an exciting opportunity for continued exploration and dialogue about metabolic-related health challenges.

DIABETES-METABOLISM RESEARCH AND REVIEWS, published by WILEY, is an esteemed academic journal focusing on the forefront of research in the fields of endocrinology, diabetes, and metabolism. Since its inception in 1999, this journal has become a crucial resource for researchers, professionals, and students, boasting an impressive impact factor that reflects its high citation rates and contribution to the field. With a 2023 classification of Q1 in several categories including Endocrinology and Internal Medicine, it ranks among the top journals globally, demonstrating its significant influence and authority. The journal serves as a platform for the dissemination of innovative research, reviews, and methodologies that advance understanding and treatment of metabolic disorders. By offering valuable insights and fostering collaboration within the scientific community, DIABETES-METABOLISM RESEARCH AND REVIEWS is essential reading for anyone involved in diabetes research and clinical practice.

The Journal of Diabetes, published by WILEY, is a premier Open Access platform since 2022, dedicated to advancing knowledge in the fields of endocrinology, diabetes, and metabolism. With an ISSN of 1753-0393 and an E-ISSN of 1753-0407, this journal provides a vital resource for researchers and practitioners looking to keep up with the latest findings and trends in diabetes management and treatment. As of 2023, it holds a commendable Q2 rating in its category and ranks #78 out of 244 in the Scopus classification, placing it in the 68th percentile, thus affirming its significance in the academic community. Covering a timeline from 2009 to 2024, the journal invites submissions that contribute to the understanding of diabetes pathophysiology, innovative therapies, and clinical practices, making it an essential read for anyone dedicated to improving patient outcomes in diabetes care.